{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:11:18Z","timestamp":1782947478828,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,22]]},"DOI":"10.7759\/cureus.40812","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T18:04:04Z","timestamp":1687457044000},"source":"Crossref","is-referenced-by-count":1,"title":["Infliximab-Induced Interstitial Pneumonitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Eyad A","family":"Makkawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal T","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed F","family":"Yehia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M","family":"Almazloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"US FDA approves Remicade for children with Crohn's disease. (2006). http.\/\/test.pharmabiz.com\/news\/us-fda-approves-remicade-for-children-with-crohn-s-disease-33546."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals M","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008, 22:847-61. 10.1016\/j.berh.2008.09.008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez R","year":"2011","unstructured":"Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al.. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011, 41:256-64. 10.1016\/j.semarthrit.2010.11.002","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2015.56343","article-title":"Pulmonary manifestations of inflammatory bowel disease","volume":"11","author":"Majewski S","year":"2015","unstructured":"Majewski S, Piotrowski W. Pulmonary manifestations of inflammatory bowel disease. Arch Med Sci. 2015, 11:1179-88. 10.5114\/aoms.2015.56343","journal-title":"Arch Med Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2007.08.009","article-title":"Pulmonary abnormalities in inflammatory bowel disease","volume":"1","author":"Schleiermacher D","year":"2007","unstructured":"Schleiermacher D, Hoffmann JC. Pulmonary abnormalities in inflammatory bowel disease. J Crohns Colitis. 2007, 1:61-9. 10.1016\/j.crohns.2007.08.009","journal-title":"J Crohns Colitis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i32.5377","article-title":"Noninfectious interstitial lung disease during infliximab therapy: case report and literature review","volume":"19","author":"Caccaro R","year":"2013","unstructured":"Caccaro R, Savarino E, D'Inc\u00e0 R, Sturniolo GC. Noninfectious interstitial lung disease during infliximab therapy: case report and literature review. World J Gastroenterol. 2013, 19:5377-80. 10.3748\/wjg.v19.i32.5377","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv135","article-title":"Six cases of lung injury following anti-tumour necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Lee HS","year":"2015","unstructured":"Lee HS, Jo KW, Shim TS, et al.. Six cases of lung injury following anti-tumour necrosis factor therapy for inflammatory bowel disease. J Crohns Colitis. 2015, 9:1053-7. 10.1093\/ecco-jcc\/jjv135","journal-title":"J Crohns Colitis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200309000-00004","article-title":"Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations","volume":"9","author":"Foster RA","year":"2003","unstructured":"Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003, 9:308-15. 10.1097\/00054725-200309000-00004","journal-title":"Inflamm Bowel Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703100421","article-title":"Interstitial pneumonitis due to mesalamine","volume":"31","author":"Pascual-Lled\u00f3 JF","year":"1997","unstructured":"Pascual-Lled\u00f3 JF, Calvo-Bonachera J, Carrasco-Miras F, Sanchez-Mart\u00ednez H. Interstitial pneumonitis due to mesalamine. Ann Pharmacother. 1997, 31:499. 10.1177\/106002809703100421","journal-title":"Ann Pharmacother"},{"key":"ref10","article-title":"What are the risks of biologic therapy in rheumatoid arthritis? An update on safety","volume":"65","author":"Weisman MH","year":"2002","unstructured":"Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl. 2002, 65:33-8.","journal-title":"J Rheumatol Suppl"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201202-0320ST","article-title":"An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer KC","year":"2012","unstructured":"Meyer KC, Raghu G, Baughman RP, et al.. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012, 185:1004-14. 10.1164\/rccm.201202-0320ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602064","article-title":"Diagnosis and management of drug-associated interstitial lung disease","volume":"91","author":"M\u00fcller NL","year":"2004","unstructured":"M\u00fcller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 2004, 91:S24-30. 10.1038\/sj.bjc.6602064","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.1.567","article-title":"Repression of bleomycin-induced pneumopathy by TNF","volume":"170","author":"Kuroki M","year":"2003","unstructured":"Kuroki M, Noguchi Y, Shimono M, et al.. Repression of bleomycin-induced pneumopathy by TNF. J Immunol. 2003, 170:567-74. 10.4049\/jimmunol.170.1.567","journal-title":"J Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/138.3.652","article-title":"Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and -independent mechanisms","volume":"138","author":"Elias JA","year":"1988","unstructured":"Elias JA. Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and -independent mechanisms. Am Rev Respir Dis. 1988, 138:652-8. 10.1164\/ajrccm\/138.3.652","journal-title":"Am Rev Respir Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00647.x","article-title":"TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation","volume":"13","author":"Sullivan DE","year":"2009","unstructured":"Sullivan DE, Ferris M, Nguyen H, Abboud E, Brody AR. TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med. 2009, 13:1866-76. 10.1111\/j.1582-4934.2009.00647.x","journal-title":"J Cell Mol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118029","article-title":"Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis","volume":"96","author":"Miyazaki Y","year":"1995","unstructured":"Miyazaki Y, Araki K, Vesin C, et al.. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest. 1995, 96:250-9. 10.1172\/JCI118029","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille C","year":"2014","unstructured":"Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014, 43:613-26. 10.1016\/j.semarthrit.2013.09.005","journal-title":"Semin Arthritis Rheum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/159546-infliximab-induced-interstitial-pneumonitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:06Z","timestamp":1707508806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/159546-infliximab-induced-interstitial-pneumonitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.40812","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,22]]}}}